Methods for detecting csf tau species with stage and progression of alzheimer's disease, and use thereof
AssigneeWashington University
InventorsRandall Bateman, Eric McDade, Nicolas Barthelemy, Kanta Horie, Yan Li
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods to quantify and analyze various CSF Tau species and the use thereof to measure pathological features and/or clinical symptoms of tauopathies, including determining the amount of time to dementia due to Alzheimer's disease, determining the time from dementia onset, staging Alzheimer's disease, guiding treatment decisions, and evaluate the clinical efficacy of certain therapeutic interventions.
Claims26
A method for measuring time to dementia onset in a subject, the method comprising
- (ai) measuring phosphorylation occupancy at residue T205 of tau and measuring microtubule-binding region (MTBR)-tau299/MTBR-tau354 ratio in a blood sample or a cerebrospinal fluid (CSF) sample obtained from the subject, or
- (aii) measuring phosphorylation occupancy at residue T205 of tau, measuring phosphorylation occupancy at residue T217 of tau, and measuring MTBR-tau212, in a blood sample or a CSF sample obtained from the subject;
- (b) using the measurements of (ai) or (aii) to calculate time to dementia onset, wherein time to dementia onset is time in years to a Clinical Dementia Rating (CDR) greater than zero;
- and
- (c) treating the subject with medical care, wherein the medical care is selected from
- (i) a prophylactic or preventative measure;
- (ii) administration of a diagnostic agent:
- or
- (iii) administration of a therapeutic agent.
- wherein the subject
- is without a cognitive or behavioral symptom of Alzheimer's disease;
- or
- has one or more cognitive or behavioral symptom of Alzheimer's disease.
A method for measuring time to dementia onset in a subject, the method comprising
- (a) processing a blood sample or a cerebrospinal fluid (CSF) sample from the subject to obtain a first population of tau species and a depleted sample, and then processing the depleted sample to obtain a second population of tau species,
- wherein the first population of tau species is enriched for N-terminal tau and/or mid-domain tau, and the second population of enriched tau species is enriched for microtubule-binding region (MTBR)-tau;
- (bi) measuring phosphorylation occupancy at residue T205 of tau in the first population of tau species and measuring MTBR-tau299/MTBR-tau354 ratio in the second population of tau species;
- (bii) measuring phosphorylation occupancy at residue T205 of tau and measuring phosphorylation occupancy at residue T217 of tau in the first population of tau species, and measuring MTBR-tau212 in the second population of tau species;
- (c) calculating time to dementia onset using the measurements of (bi) or (bii), wherein time to dementia onset is time in years to a Clinical Dementia Rating (CDR) greater than zero;
- and
- (d) treating the subject with medical care, wherein the medical care is selected from
- (i) a prophylactic or preventative measure;
- (ii) administration of a diagnostic agent;
- or
- (iii) administration of a therapeutic agent.
- wherein the subject
- is without a cognitive or behavioral symptom of Alzheimer's disease;
- or
- has one or more cognitive or behavioral symptom of Alzheimer's disease.
(canceled)
(canceled)
(canceled)
-34. (canceled)
A method for measuring change in cognition in a subject, the method comprising
- (a) measuring phosphorylation occupancy at one or more residue of tau selected from T111, T153, T181, T217 and T231 in a blood sample or a cerebrospinal fluid (CSF) sample obtained from the subject, and
- measuring at least one of microtubule-binding region (MTBR)-tau275, MTBR-tau299, and MTBR-3R in a blood sample or a CSF sample obtained from the subject, and
- (b) using the measurements of (a) to calculate a change in cognition.
Dependencies are inferred from the claim text.